Sign inJoin waitlistJoin the waitlist

Keith August

Hematology, Oncology and Blood and Marrow Transplantation · University of Kansas School of Medicine

Credentials: · · · · · · ·

History

University of Kansas School of Medicine
Present

Pediatric Hematology/Oncology
Emory University School of Medicine
2005–2008
Pediatrics
2002–2005
University of Oklahoma College of Medicine
1998–2002

Research

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Clinical Cancer Research · 2018 · 198 citations
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
Leukemia · 2019 · 165 citations
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Journal of Clinical Oncology · 2022 · 138 citations

EG
Erin Guest
6 papers
Weijie Li
6 papers
John Levine
5 papers
LC
Linda Cooley
5 papers
Alan Gamis
4 papers
JH
Julia Hays
4 papers
Michael Boyer
4 papers
Michael Pulsipher
4 papers
Midhat Farooqi
4 papers · 2 as a fellow
Stephan Grupp
4 papers
Terrie Flatt
4 papers
Theodore Laetsch
4 papers

Grants

Increased Sensitivity of Minimal Residual Disease Monitoring Using Peripheral Blood in Pediatric Patients with Acute Lymphoblastic Leukemia
National Cancer Institute · R33
PI · $905.8K · University of Kansas Lawrence
2019–2024

Clinical trials

Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL
Principal investigator · Not yet recruiting
University of Kansas Medical Center
2026–2028
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Principal investigator · Terminated · Phase 2
Children's Mercy Hospital Kansas City
2015–2017
Quality of End-of-Life Care for Children With Cancer
Site PI · Recruiting
Children's Oncology Group
2026–2031
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031